Weighing in on weight loss drugs

In recent months, we’ve seen a flurry of headlines discussing the emergence of weight loss drugs, collectively referred to as GLP-1 agonists, and their potential to support obesity care. Digital health startups have responded, from seizing the moment (Ro, Teladoc) by offering prescriptions digitally, to sticking deliberately to behavior change offerings (Omada), to providing a range of services somewhere between directly offering prescriptions and addressing obesity without a medication component.

While there’s considerable excitement about how weight loss drugs are transforming obesity’s standard of care, providers are cautioning that weight loss drugs aren’t a silver bullet. Clinical leaders emphasize the need to take a comprehensive approach to obesity care that accounts for psychological and socioeconomic factors, given the complexity of the disease. In our latest piece, we explore how technology solutions can play a critical role in delivering whole person obesity care. As the market evolves rapidly, it’s an optimal moment for life sciences companies, payers, and providers to integrate digital into therapeutic innovations and care strategies and support meaningful change for patients.

Headlines

Clinical Trials And Tribulations: What Does CVS’ Exit Mean For Other Retailers And Sponsors?
Implications of CVS’ plan to sunset its clinical trials business by end of next year Rock Health